Xeris Pharmaceuticals Inc Total Liabilities

Latest as of June 2026: $421.64 Million USD

Xeris Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Xeris Pharmaceuticals Inc (XERS) has total liabilities worth $421.64 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check XERS asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Xeris Pharmaceuticals Inc (2016–2025)

Total liabilities of Xeris Pharmaceuticals Inc from 2016 to 2025. This chart illustrates how Xeris Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Xeris Pharmaceuticals Inc (XERS) long-term investment share to see how much of total assets are deployed in long-term investments.

Xeris Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Xeris Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Central Plaza Hotel Public Company Limited BK:CENTEL-R	Thailand	฿39.97 Billion
Arlo Technologies NYSE:ARLO	USA	$216.06 Million
Guangdong Marubi Biotechnology Co SHG:603983	China	CN¥1.20 Billion
Wolverine World Wide Inc NYSE:WWW	USA	$1.21 Billion
Jiangxi Ganyue Expressway Co Ltd SHG:600269	China	CN¥16.49 Billion
Henan Zhongyuan Expressway Co Ltd SHG:600020	China	CN¥41.36 Billion
Lingyun Ind SHG:600480	China	CN¥10.45 Billion
GCH Technology Co. Ltd. A SHG:688625	China	CN¥1.60 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Xeris Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Xeris Pharmaceuticals Inc assets under control.

Liquidity & Leverage Metrics

Xeris Pharmaceuticals Inc Total Liabilities Ratios Explained

Xeris Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	1.45	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-43.32	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.02	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Xeris Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Xeris Pharmaceuticals Inc (2016–2025)

The table below shows the annual total liabilities of Xeris Pharmaceuticals Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	$369.84 Million	+4.87%
2024-12-31	$352.68 Million	+7.07%
2023-12-31	$329.38 Million	+10.04%
2022-12-31	$299.33 Million	+43.13%
2021-12-31	$209.13 Million	+121.18%
2020-12-31	$94.55 Million	0.00%
2019-12-31	$94.55 Million	+111.89%
2018-12-31	$44.62 Million	-56.61%
2017-12-31	$102.83 Million	+57.07%
2016-12-31	$65.47 Million	--

About Xeris Pharmaceuticals Inc

NASDAQ:XERS USA Drug Manufacturers - Specialty & Generic

Market Cap

$1.91 Billion

Market Cap Rank

#7274 Global

#2239 in USA

Share Price

$10.46

Change (1 day)

+1.06%

52-Week Range

$5.29 - $11.13

All Time High

$27.23